Standard care

Phase 3

MMuhammad Aamir Latif

Standard care is one of 28 therapeutic programs targeting Septic Shock. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Septic ShockCompleted

Burn InjuryNot yet recruiting

Septic ShockPreclinical

Completed

Burn InjuryPhase 3

Not yet recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

Standard care

MMuhammad Aamir Latif

Phase 3

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Coly-Mycin M

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

Burn Injury

NCT07212998

Clinical

Trials by Indication[1]

Burn Injury1 trial

Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

Not yet recruiting·JJason Sperry·Phase 3·NCT07212998·750 enrolled

Septic Shock1 trial

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Completed·MMuhammad Aamir Latif·Preclinical·NCT07313670·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard care. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard care. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Muhammad Aamir Latif company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMuhammad Aamir Latif

Standard care

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Burn Injury1 trial

Septic Shock1 trial

References

Drug Info

Quick Facts

Related News